Department of Molecular Immunology, Institute for Molecular Medicine, 16371 Gothard Street, Suite H, Huntington Beach, CA, 92647, USA,
Clin Exp Metastasis. 2014 Feb;31(2):185-98. doi: 10.1007/s10585-013-9619-0. Epub 2013 Oct 6.
It is believed that primary tumor resection modulates host-tumor immune interaction, but this has not been characterized in a stringent breast cancer tumor model. This report, using the 4T1 murine mammary tumor model, characterizes for the first time the dynamic longitudinal changes in immunosuppressive and effector components of the immune system after resection of an established orthotopic primary tumor with a defined natural history of developing lung metastases. More specifically, we analyzed changes of absolute numbers and frequencies of MDSC, regulatory T cells (Treg), as well as activated CD4 and CD8 positive T cells in spleens and, in some studies, lungs of 4T1 tumor-bearing mice and mice after primary tumor resection. Importantly, using mathematical analyses we established that primary resection of an orthotopic tumor had created a "window of opportunity" with decreased tumor-associated immune suppression that existed for approximately 10 days. Although tumor resection did slightly prolong survival, it did not affect the ultimate development of metastatic disease since animals with resected tumors or intact primary tumors eventually died by day 47 and 43, respectively. This window of opportunity likely occurs in humans providing a rationale and parameters for integration and testing of immunotherapeutic strategies in this critical "window of opportunity" to combat the development of metastatic disease.
人们认为原发肿瘤切除术可以调节宿主-肿瘤免疫相互作用,但这在严格的乳腺癌肿瘤模型中尚未得到证实。本报告首次使用 4T1 鼠乳腺肿瘤模型,描述了在具有明确发生肺转移自然史的原位原发性肿瘤切除后,免疫系统中免疫抑制和效应成分的动态纵向变化。更具体地说,我们分析了在原发性肿瘤切除后,4T1 荷瘤小鼠和小鼠的脾脏中髓源性抑制细胞(MDSC)、调节性 T 细胞(Treg)以及活化的 CD4 和 CD8 阳性 T 细胞的绝对数量和频率的变化,在一些研究中还分析了肺部的变化。重要的是,我们通过数学分析确定,原发性肿瘤切除术创造了一个“机会之窗”,在此期间肿瘤相关免疫抑制降低,大约持续 10 天。尽管肿瘤切除术略微延长了生存时间,但它并没有影响转移性疾病的最终发展,因为接受肿瘤切除术或完整原发性肿瘤的动物最终分别在第 47 天和第 43 天死亡。这个机会之窗可能在人类中存在,为在这个关键的“机会之窗”中整合和测试免疫治疗策略提供了理由和参数,以对抗转移性疾病的发展。